Effects of IVB on the area of capillary nonperfusion in BRVO eyes

Article

Occurrence of, a significantly increased area of capillary nonperfusion is significantly low in eyes with branch retinal vein occlusion (BRVO) after administration of intravitreal bevacizumab (IVB),

Occurrence of, a significantly increased area of capillary nonperfusion is significantly low in eyes with branch retinal vein occlusion (BRVO) after administration of intravitreal bevacizumab (IVB), according to a study published in Retina.

Dr Terui Takayuki et al., Department of Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Japan, studied 58 eyes of 58 patients with macular oedema secondary to BRVO. One month before and one month after IVB, fluorescein angiography was performed on all patients. Early-phase fluorescein angiography imaging was used to measure the area of capillary nonperfusion and blockages of the fluorescence by the retinal haemorrhage were determined with retinal photographs.

Before IVB 37 of the 58 eyes did not show any signs of capillary nonperfusion and after one month of IVB 3 of the 37 eyes developed capillary nonperfusion. The area of nonperfusion in these 3 eyes was 0.13, 0.47 and 0.60 optic disc area (DA).

Before IVB 21 of the 58 eyes had capillary nonperfusion and the mean area was 3.45 ± 4.66 DA before the IVB and 3.45 ± 5.19 DA 1 month after the IVB.

Only one eye of the 58 studied presented with an increase in the area of capillary nonperfusion after IVB. The incidence of an increase in capillary nonperfusion area post IVB treatment is significantly low in eyes with BRVO.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.